A Phase 2a trial of Teplizumab and RN168 in patients with new onset type 1 diabetes mellitus
Principal Investigator
Kevan Herold | Yale School of Medicine | New Haven, CT
Locations
Study Code
ITN083AI
Study Status
Withdrawn
Article Citations
(Scroll Down for More)
